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Endothelin 1 from the vascular 
endothelium contributes  
to blood pressure control
Kisanuki et al., Hypertension 2010; 56: 121–128; doi:10.1161/
HYPERTENSIONAHA.109.138701
Endothelin 1 (ET-1) was identified as a potent vasoconstric-
tor agent isolated from endothelial cells, and although it is 
expressed by various cell types, endothelial cells are its most 
abundant source in the adult. ET-1 acts on two distinct G 
protein-coupled receptors, ETA and ETB, which are found in 
various vascular and nonvascular tissues. Vascular smooth 
muscle cells express both ETA and ETB, which mediate a 
direct vasoconstrictor action of ET-1. In contrast, endothelial 
cells express only ETB, which exerts vasodilator effects via the 
release of nitric oxide and prostacyclin. In addition to direct 
vascular actions, ET-1 and its receptors also affect blood pres-
sure via activity in the collecting ducts and perhaps the brain 
and the adrenal gland. Renal collecting duct-specific ET-1 
knockout mice or ETB knockout mice exhibit salt retention 
and hypertension. The potential role of ET-1 in vascular tone 
has been studied with blockers of the ETA and ETB receptors, 
but the precise physiological roles of endothelial ET-1 in the 
regulation of blood pressure have remained unclear, as ET-
1-deficient mice die shortly after birth. To address this ques-
tion, Kisanuki et al. used Cre/loxP recombination (ET-1flox/
flox;Tie2-Cre mice) to generate a mouse strain in which ET-1 
is disrupted, specifically in endothelial cells. They found that 
ET-1 peptide levels in plasma, heart, lung, kidney, and brain 
homogenates were reduced by more than 65%. This reduction 
was associated with a blood pressure about 10 mm Hg lower 
than that of controls (Figure). 
These results establish that endothelial-derived ET-1 is 
involved in blood pressure maintenance. Because collecting 
duct-specific ET-1 deletion causes salt retention and hyper-
tension, it is likely that the lower blood pressure of the mice 
with deleted endothelial ET-1 is due to loss of a normal vaso-
constrictor action by the peptide. If confirmed, these results 
indicate that, unlike angiotensin II, vasopressin, and atrial 
natriuretic peptide, ET-1 has vascular and renal sodium 
handling discordant actions.
Juan Oliver
A B-cell signature associated with 
renal transplant tolerance in humans
Newell et al., J Clin Invest 2010; 120: 1836–1847; doi:10.1172/JCI39933
Sagoo et al., J Clin Invest 2010; 120: 1848–1861; doi:10.1172/JCI39922
Most long-term practicing nephrologists have encountered 
or are aware of a rare patient who received a cadaveric kidney 
transplant that maintained allograft function despite discontinu-
ation of immunosuppression. Needless to say, such patients have 
allograft tolerance, a highly desirable condition in which good 
allograft function is maintained in the absence of immunosup-
pressive therapy. Graft tolerance has been achieved in numerous 
animal models of kidney transplantation. Attempts to induce it 
in humans have been far less successful, and the fear of potential 
loss of the graft during immune-suppression minimization or 
withdrawal has not encouraged experimentation. Two recent 
studies have approached this issue by attempting to identify 
biomarkers and mechanisms active in subjects with engrafted 
kidneys that, despite sustained discontinuation of immunosup-
pression (spontaneously by the patients or because of intolerable 
side effects), maintained graft function. Newell et al. obtained 
data from 25 patients with allograft tolerance and compared 
them with data from kidney transplant recipients on immune 
suppression and from normal volunteers. With flow cytom-
etry of lymphocyte sub-populations plus blood and urine gene 
expression using gene arrays and PCR validation, they found 
that B cell-related genes were strongly expressed in the toler-
ant patients. Tolerant subjects showed increased expression of 
multiple B-cell differentiation genes, and a set of just three of 
these genes distinguished tolerant from non-tolerant recipients. 
Sagoo et al. screened for potential biomarkers and bioassays in 
11 tolerant kidney transplant recipients and compared them 
with those of patients on immune suppression and exhibiting 
chronic allograft injury and healthy controls. They found that 
tolerant patients had an expansion of peripheral blood B and 
natural killer lymphocytes, fewer activated CD4+ T cells, a lack 
of donor-specific antibodies, donor-specific hyporesponsive-
ness of CD4+ T cells, and a high ratio of forkhead box P3 to 
α-1,2-mannosidase gene expression. The authors of both studies 
shared samples, and in cross-validation studies they confirmed 
a strong association between the kidney allograft-tolerant state 
and B cell-related genes and markers.
Although the exact significance of these results and their 
potential clinical application remain to be established, the two 
studies strongly suggest a fruitful avenue of research on the 
mechanisms of renal transplant survival.
Juan Oliver
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Telemetric 24-hour measurement of systolic blood pressures of ET-1flox/flox; 
Tie2-Cre+ mice and ET-1flox/flox;Cre– mice (controls). ZT, Zeitgeber time.
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Methylation determines  
fibroblast activation and 
fibrogenesis in the kidney
Bechtel et al., Nat Med 2010; 16: 544–550; doi:10.1038/nm.2135
 A general hallmark of fibrosis, as opposed to physiological wound 
healing, is the active scarring that does not cease once the initial 
insult has been contained and, instead, becomes a continuous pro-
cess.1,2 What perpetuates scarring in the setting of fibrosis is not yet 
known. Activated fibroblasts are considered principal mediators 
of fibrogenesis. Bechtel et al. hypothesized that epigenetic modi-
fications cause this perpetuation of fibrogenesis. They found that 
hypermethylation of RASAL1, encoding an inhibitor of the Ras 
oncoprotein, is associated with the perpetuation of fibroblast acti-
vation and fibrogenesis in the kidney. RASAL1 hypermethylation 
is mediated by the methyltransferase Dnmt1 in renal fibrogenesis, 
and kidney fibrosis is ameliorated in Dnmt1+/− heterozygous mice 
(Figure). These studies further highlight differences between fibro-
genesis and physiological repair. Fibroblast activation is associated 
with transcriptional RASAL1 repression in the settings of both 
physiological kidney repair and pathological fibrogenesis. How-
ever, whereas reversible fibroblast activation typical of physiological 
repair is associated with reversible RASAL1 suppression without its 
hypermethylation, sustained fibroblast activation typical of fibrotic 
kidneys is associated with irreversible RASAL1 expression due to 
hypermethylation of the RASAL1 promoter. This finding suggests 
that hypermethylation perpetuates fibroblast activation, and ulti-
mately fibrogenesis, by imprinting pathways of fibroblast activation 
that are engaged during the transient fibroblast activation typical of 
physiological repair. Although these elegant studies demonstrated 
that the RASAL1 hypermethylation correlates strongly with fibro-
genesis and the absence of RASAL1 methylation correlates with 
physiological repair upon kidney injury, studies manipulating 
RASAL1 in vivo are needed to elucidate whether RASAL1 silencing 
alone is sufficient to induce fibrogenesis in the kidney or whether 
it modulates the rate at which induced fibrosis progresses.
Future studies should explain the utility of methylated genes as 
diagnostic markers to predict fibrosis and the possible therapeutic 
efficacy of methylation inhibitors in progression of fibrogenesis.
Marc De Broe
1J Am Soc Nephrol 1996; 7: 2495–2508. 2Kidney Int 1991; 39: 550–556.
Cystatin C and contrast-induced 
acute kidney injury
Briguori et al., Circulation 2010; 121: 2117–2122; doi:10.1161/
CIRCULATIONAHA.109.919639
Multiple epidemiologic studies have defined the utility of cystatin 
C in various clinical settings. Briguori et al. attempted to define 
the utility of changes in cystatin C and sought in the short term 
to identify patients with acute kidney injury (AKI) before their 
elevation in serum creatinine.
Patients undergoing cardiac catheterization were prospectively 
enrolled from January 2007 to September 2009 at a single center. 
Exclusion criteria were preexisting dialysis, multiple myeloma, 
pulmonary edema, acute myocardial infarction, recent exposure 
to contrast media, pregnancy, and the use of certain medications. 
Participating patients were treated with intravenous sodium bicar-
bonate and N-acetylcysteine before and after receiving their con-
trast media. Serum creatinine and cystatin C were measured 24 
hours before and 24 hours after the administration of the contrast 
media. The purpose was to assess whether changes in cystatin C 
level could predict who would go on to have an increase in serum 
creatinine of at least 0.3 mg/dl more and either need dialysis or die 
within 12 months.
Enrolled patients had a mean age of 70 years and a median 
serum creatinine of 1.64 mg/dl. The cohort of 410 patients received 
a mean volume of contrast of 165 ml and experienced a rate of AKI 
(defined as an increase in serum creatinine greater than 0.3 mg/
dl) of 8.2%. Changes in cystatin C and their ability to predict AKI 
were calculated with multiple definitions of a ‘clinically significant 
change.’ Any increase in cystatin C was 100% sensitive in detect-
ing all events of AKI at the expense of a sensitivity of 65.2%. Any 
increase in cystatin C, therefore, gave a negative predictive value of 
100%, with a positive predictive value of only 20.6%. An increase 
of cystatin C of at least 10% maintained the same 100% sensitivity 
but improved the specificity to 85.9% and the positive predictive 
value to 39.1%. 
This analysis demonstrates some utility in the use of changes in 
cystatin C to predict the patients who may go on to experience a 
rise in serum creatinine following the administration of contrast 
media. The degree to which the specificity and positive predictive 
value may overcall the likelihood of AKI should be considered. 
The cost of hospitalizing and monitoring patients with a rise in 
cystatin C following the administration of contrast may not justify 
the benefit. However, if the care and surveillance can be delivered 
on an outpatient basis, it may be an exceptionally useful tool to 
identify patients who require laboratory measures as outpatients 
for additional scrutiny in the short term.
Lynda Szczech
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5′-Azacytidine ameliorates experimental renal fibrosis. (a) Interstitial 
fibrotic area in Masson’s trichrome-stained sections. The graph 
summarizes average values at the indicated time points of each group. 
(b) Average serum creatinine concentrations at the indicated time points. 
(c–e) Relative stained area in frozen sections that were labeled with 
antibodies against fibroblast-specific protein-1 (FSP-1) (c), α-smooth 
muscle actin (α-SMA) (d), or type I collagen (e). Data are presented as 
means ± s.e.m. FA, folic acid; 5′-Aza, 5′-azacytidine.
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